Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · West Pharmaceutical Services (WST)

West Pharmaceutical raises 2026 guidance after first-quarter sales rise 21%

Positive Impact 4 of 5 earnings Written later

West Pharmaceutical reported first-quarter 2026 net sales of $844.9 million, up 21.0% from a year earlier, and diluted EPS of $1.92, up 56.1%. The company raised its full-year 2026 net sales guidance to $3.295 billion to $3.350 billion and its adjusted-diluted EPS guidance to $8.40 to $8.75, and it repurchased $297.6 million of its shares during the quarter.

Key points

  • First-quarter net sales were $844.9 million, up 21.0% reported and 15.3% organic, versus $698.0 million a year earlier.
  • Diluted EPS was $1.92, up from $1.23; adjusted-diluted EPS was $2.13, up 46.9%.
  • Full-year 2026 adjusted-diluted EPS guidance rose to $8.40 to $8.75, from $7.85 to $8.20.
  • Cash and cash equivalents fell to $521.4 million at March 31, 2026, from $791.3 million at December 31, 2025, after share repurchases.

The filing

CompanyWest Pharmaceutical Services (WST)
Form8-K, current report
Filed with the SECApr 23, 2026, 7:11 AM ET
Accession number0000105770-26-000047

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.